- Home
- CARS vs DNTH Comparison
CARS vs DNTH Comparison
Compare CARS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- DNTH
- Stock Information
- Founded
- CARS 1998
- DNTH 2015
- Country
- CARS United States
- DNTH United States
- Employees
- CARS N/A
- DNTH N/A
- Industry
- CARS Motor Vehicles
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- DNTH Health Care
- Exchange
- CARS Nasdaq
- DNTH Nasdaq
- Market Cap
- CARS 745.2M
- DNTH 651.8M
- IPO Year
- CARS 2017
- DNTH N/A
- Fundamental
- Price
- CARS $12.63
- DNTH $20.74
- Analyst Decision
- CARS Strong Buy
- DNTH Strong Buy
- Analyst Count
- CARS 5
- DNTH 8
- Target Price
- CARS $17.30
- DNTH $53.00
- AVG Volume (30 Days)
- CARS 885.9K
- DNTH 326.6K
- Earning Date
- CARS 08-07-2025
- DNTH 08-07-2025
- Dividend Yield
- CARS N/A
- DNTH N/A
- EPS Growth
- CARS 69.36
- DNTH N/A
- EPS
- CARS 0.63
- DNTH N/A
- Revenue
- CARS $717,845,000.00
- DNTH $4,854,000.00
- Revenue This Year
- CARS $2.68
- DNTH N/A
- Revenue Next Year
- CARS $3.71
- DNTH N/A
- P/E Ratio
- CARS $20.03
- DNTH N/A
- Revenue Growth
- CARS 0.68
- DNTH 17.87
- 52 Week Low
- CARS $9.56
- DNTH $13.37
- 52 Week High
- CARS $20.47
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- CARS 50.65
- DNTH 53.56
- Support Level
- CARS $12.41
- DNTH $18.08
- Resistance Level
- CARS $13.15
- DNTH $21.18
- Average True Range (ATR)
- CARS 0.60
- DNTH 1.50
- MACD
- CARS -0.07
- DNTH -0.10
- Stochastic Oscillator
- CARS 73.36
- DNTH 59.38
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.